O-4310

O-4310, also known as 1-isopropyl-6-fluoropsilocin, is a serotonin receptor agonist of the tryptamine family. It is the 1-isopropylated and 6-fluorinated derivative of the serotonergic psychedelic psilocin.

Pharmacology

The drug is said to be a serotonin 5-HT_2A receptor agonist and to be highly selective for activation of this receptor over the closely related serotonin 5-HT_2B and 5-HT_2C receptors. Its at the serotonin 5-HT_2A receptor was reported to be 5nM and it was said to have an of 89% relative to serotonin. Conversely, O-4310 was said to be inactive at the serotonin 5-HT_2B receptor, with no or reported for this receptor, and was claimed to have an of 592nM at the serotonin 5-HT_2C receptor with an of approximately 50%. Hence, O-4310 appears to show about 118-fold selectivity for activation of the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor.
The pharmacodynamic activity of O-4310 was briefly described in a patent but not in the published scientific literature. If the reported data are accurate, O-4310, along with other drugs like 25CN-NBOH and (S,''S'')-DMBMPP, would be one of the most selective known agonists of the serotonin 5-HT_2A receptor over the other serotonin 5-HT₂ receptors.

O-4310 was patented by Bryan Roth and colleagues in 2006 and the patent was assigned to the American pharmaceutical company Organix Inc. The drug was also employed in an animal study and described in the scientific literature by a group of Iranian researchers in 2017.